These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28274536)

  • 41. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA; Rudakova AV
    Vopr Onkol; 2015; 61(4):676-80. PubMed ID: 26571844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
    Fraser A
    N Z Med J; 2017 Mar; 130(1451):11-20. PubMed ID: 28253240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.
    Okami J; Taniguchi K; Higashiyama M; Maeda J; Oda K; Orita N; Koizumi K; Kodama K; Kato K
    Oncology; 2007; 72(3-4):234-42. PubMed ID: 18176089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
    Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
    Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
    Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New kinase inhibitor approved for metastatic lung cancer.
    Thompson CA
    Am J Health Syst Pharm; 2013 Aug; 70(16):1363. PubMed ID: 23903470
    [No Abstract]   [Full Text] [Related]  

  • 49. [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
    Taus Á
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():30-5. PubMed ID: 27426246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EGFR mutations in non-small-cell lung cancer.
    Hung JJ; Jeng WJ; Hsu WH; Liu JS; Wu YC
    Lancet Oncol; 2010 May; 11(5):412-3; author reply 413. PubMed ID: 20434712
    [No Abstract]   [Full Text] [Related]  

  • 51. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
    Hammond D; Montalban-Bravo G
    Curr Hematol Malig Rep; 2021 Oct; 16(5):405-417. PubMed ID: 34499330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EGFR mutations and EGFR tyrosine kinase inhibitors.
    Torri V; Broggini M; Garassino MC
    Lancet Oncol; 2015 Jul; 16(7):746-8. PubMed ID: 26051233
    [No Abstract]   [Full Text] [Related]  

  • 53. A favourable effect of recombinant human erythropoietin in three cases of leukaemic transformation from chronic myelomonocytic leukaemia.
    Uziel L; Fabrizi I; Zighetti ML; Carpani G; Rosti A; Moroni GA; Marmont A
    Br J Haematol; 1992 Feb; 80(2):260-2. PubMed ID: 1550789
    [No Abstract]   [Full Text] [Related]  

  • 54. Leukemia cutis in a patient with chronic myelomonocytic leukemia.
    Claßen A; Kitz J; Perske C; Overbeck T; Bertsch HP; Schön MP; Lippert U
    J Dtsch Dermatol Ges; 2018 Jan; 16(1):81-83. PubMed ID: 29288601
    [No Abstract]   [Full Text] [Related]  

  • 55. A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
    Burgstaller S; Stauder R; Kuehr T; Lang A; Machherndl-Spandl S; Mayrbaeurl B; Noesslinger T; Petzer A; Valent P; Greil R; Thaler J
    Leuk Lymphoma; 2018 May; 59(5):1121-1126. PubMed ID: 28853315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
    Montalban-Bravo G; Thongon N; Rodriguez-Sevilla JJ; Ma F; Ganan-Gomez I; Yang H; Kim YJ; Adema V; Wildeman B; Tanaka T; Darbaniyan F; Al-Atrash G; Dwyer K; Loghavi S; Kanagal-Shamanna R; Song X; Zhang J; Takahashi K; Kantarjian H; Garcia-Manero G; Colla S
    Cell Rep Med; 2024 Jun; 5(6):101585. PubMed ID: 38781960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.
    Taoka K; Arai S; Kataoka K; Hosoi M; Miyauchi M; Yamazaki S; Honda A; Aixinjueluo W; Kobayashi T; Kumano K; Yoshimi A; Otsu M; Niwa A; Nakahata T; Nakauchi H; Kurokawa M
    Sci Rep; 2018 Oct; 8(1):15855. PubMed ID: 30367142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report.
    Hu L; Zheng B; Fu L; Hu M
    Medicine (Baltimore); 2020 Oct; 99(44):e23030. PubMed ID: 33126392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy.
    Koopman B; Hiddinga BI; Platteel I; Kluiver JL; Timens W; Mulder AB; van Doesum JA; Schuuring E; Diepstra A; van Kempen LC
    Histopathology; 2021 Jun; 78(7):1043-1046. PubMed ID: 33410163
    [No Abstract]   [Full Text] [Related]  

  • 60. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.
    Saliba AN; Litzow MR; Gangat N; Al-Kali A; Foran JM; Hogan WJ; Palmer JM; Mangaonkar AA; Tefferi A; Patnaik MM
    Am J Hematol; 2021 Nov; 96(11):E433-E436. PubMed ID: 34428328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.